Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.

Blood - 16 Oct 2014

Ricciardelli Ida, Blundell Michael Patrick, Brewin Jennifer, Thrasher Adrian, Pule Martin, Amrolia Persis J

Abstract excerpt

Epstein-Barr virus (EBV)-associated posttransplant lymphoma (PTLD) is a major cause of morbidity/mortality after hematopoietic stem cell (SCT) or solid organ (SOT) transplant. Adoptive immunotherapy with EBV-specific cytotoxic lymphocytes (CTLs), although effective in SCT, is less successful afte...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcineurin
Share to Calcineurin Inhibitors
Share to Epstein-Barr Virus Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Lymphoma

Share to Mice, Inbred NOD

Share to Tacrolimus

Share to Transduction, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 25185261
DOI: 10.1182/blood-2014-01-553362
PMCID: PMC4199953

Genes

SCT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25185261-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.PMID 25185261Read ↗

Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy.Semantic proximity Read ↗

Immunotherapeutic strategies for EBV-associated malignancies.Semantic proximity Read ↗

Redirecting T Cells against Epstein–Barr Virus Infection and Associated OncogenesisSemantic proximity Read ↗

Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.Semantic proximity Read ↗

Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.Semantic proximity Read ↗

CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant RecipientsSemantic proximity Read ↗

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.Semantic proximity Read ↗

Epstein–Barr virus, rapamycin, and host immune responsesSemantic proximity Read ↗

K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.Semantic proximity Read ↗

In vivo selection of MGMT(P140K) lentivirus–transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioningSemantic proximity Read ↗

Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative DiseaseSemantic proximity Read ↗

Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.